<DOC>
	<DOCNO>NCT00063141</DOCNO>
	<brief_summary>The purpose study determine whether overall survival prolong subject metastatic , epidermal growth factor receptor ( EGFR ) -positive colorectal cancer treat cetuximab combination irinotecan compare irinotecan alone second-line therapy follow treatment fluoropyrimidine oxaliplatin base , non-irinotecan-containing regimen .</brief_summary>
	<brief_title>Study Irinotecan Cetuximab Versus Irinotecan Second-Line Treatment Patients With Metastatic , EGFR-Positive Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically document colorectal cancer EGFRpositive immunohistochemistry [ IHC ] ( may base archival sample ) metastatic . Prior oxaliplatin administer firstline treatment metastatic colorectal cancer . Prior fluoropyrimidinecontaining regimen ( 5fluorouracil [ 5FU ] , capecitabine , uracil/tegafur [ UFT ] ) , firstline treatment metastatic disease . A serious uncontrolled medical disorder , opinion Investigator , would impair ability subject receive protocol therapy Unresolved diarrhea , bowel obstruction , history inflammatory bowel disease Known document brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>